Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 avr. 2019 01h59 HE | Source: Genmab A/S

Genmab Announces Submission of Supplemental New Drug Application in Japan for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Media Release Copenhagen, Denmark, April 5, 2019 Supplemental new drug application (sNDA) submitted in Japan for daratumumab in combination with lenalidomide and dexamethasone as treatment for...
03 avr. 2019 07h33 HE | Source: Genmab A/S

Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma

Company Announcement Phase III study to examine daratumumab plus lenalidomide as maintenance treatment in patients with newly diagnosed multiple myelomaStudy utilizes the subcutaneous formulation of...
02 avr. 2019 12h21 HE | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; April 2, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 146,961 shares as a consequence of the exercise of employee warrants. ...
02 avr. 2019 08h58 HE | Source: Genmab A/S

Genmab to Present at the H.C. Wainwright & Co. Global Life Sciences Conference

Media Release Copenhagen, Denmark, April 2, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the H.C. Wainwright &...
29 mars 2019 13h57 HE | Source: Genmab A/S

Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; March 29, 2019 – Following Genmab A/S’ (Nasdaq Copenhagen: GEN) Annual General Meeting held on March 29, 2019, the Company’s Board of Directors met to...
29 mars 2019 08h11 HE | Source: Genmab A/S

Passing of Genmab A/S’ Annual General Meeting

Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2019, the Annual Report for 2018 was approvedDischarge was given to the Board of Directors and the Executive Management...
27 mars 2019 05h12 HE | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with...
26 mars 2019 09h20 HE | Source: Genmab A/S

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are...
22 mars 2019 06h48 HE | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment for newly diagnosed multiple myeloma patients...
11 mars 2019 04h12 HE | Source: Genmab A/S

Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations

Media ReleaseCopenhagen, Denmark, March 11, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Marisol Peron has been appointed Corporate Vice President, Communications and Investor...

Page précédente

Page suivante